-
HNRNPU Lactylation Rewires Cervical Cancer Metabolism
2026-10-07
A 2026 Advanced Science study identifies HNRNPU lysine 181 lactylation as a lactate-responsive mechanism that stabilizes HNRNPU, preserves PHGDH mRNA, and activates serine biosynthesis in cervical cancer. The work connects a metabolic signal to post-transcriptional RNA regulation and provides a rationale for studying this axis, while its pharmacological findings require validation beyond the reported models.
-
MRTFA-KCNMB1 Axis in Cancer Cell Stiffness
2026-10-07
Gajda et al. identify potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. The study connects softer cancer cells with immune evasion and metastatic colonization, while genetic or pharmacological BK-channel activation increased stiffness and improved immune-mediated clearance in preclinical models.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-10-06
A 2026 study links berberine’s protection against angiotensin II-induced atrial remodeling to activation of the SIRT6-AMPK axis and suppression of NLRP3 inflammasome signaling. Its integrated human-sample, bioinformatics, and murine-model evidence supports a mechanistic hypothesis for atrial fibrillation prevention, while remaining preclinical and model-dependent.
-
Cepharanthine in Endometriosis: Evidence and Limits
2026-10-06
A 2026 study evaluates Cepharanthine across stromal-cell models, patient-derived endometrial organoids, and a murine peritoneal endometriosis model. Its findings connect reduced lesion growth with G0/G1 arrest, DNA-damage signaling, impaired repair-associated markers, and apoptosis, while important questions about selectivity, safety, and clinical translation remain unresolved.
-
Concanamycin A: From V-ATPase to Autophagy
2026-10-05
Concanamycin A is a V-type H+-ATPase inhibitor that reveals how organelle acidification shapes autophagy, trafficking, and cancer biology research. This article connects its pharmacological mechanism with a landmark Arabidopsis study while clarifying what the evidence can—and cannot—show.
-
2-D08 and SUMOylation: Evidence and Limits
2026-10-04
2-D08, also known as 2’,3’,4’-trihydroxyflavone, is described as a mechanistically distinct SUMOylation inhibitor, but current evidence supports its use as a research tool rather than a validated therapy. A 2026 bronchopulmonary dysplasia study strengthens interest in SUMO-regulated mitochondrial quality control while providing no direct evidence for 2-D08 in that disease model.
-
(R)-MG132: Evidence and Research Context
2026-10-03
(R)-MG132 is described by APExBIO as a markedly less active stereoisomer of MG-132 and a potential negative control for proteasome-related research. This overview separates supplier-reported properties from peer-reviewed evidence, explains its conceptual role in ubiquitin-proteasome system research, and examines why findings from a recent HNRNPU lactylation study in cervical cancer should not be treated as direct evidence for (R)-MG132 activity or applicability.
-
5-AZA-2'-Deoxycytidine Toxicity in Mice
2026-10-02
Momparler and Frith established a clinically motivated mouse toxicology framework for continuous intravenous 5-AZA-2'-deoxycytidine, combining lethality estimation with serial hematologic and histopathologic assessment. The findings define dose-limiting marrow and gastrointestinal injury, while also showing substantial recovery of several lesions, providing an important safety foundation for later Decitabine research.
-
Exo1 and the Next Era of Tumor Vesicle Research
2026-10-01
Exo1, also known as methyl 2-(4-fluorobenzamido)benzoate, offers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership guide connects that tool to tumor extracellular vesicle research while separating experimentally supported conclusions from translational hypotheses.
-
Dorsomorphin 2HCl: Translating AMPK Biology
2026-10-01
Dorsomorphin 2HCl is a valuable AMPK inhibitor and BMP pathway probe for testing causal biology across hepatic metabolism, osteogenesis, and iron homeostasis. This thought-leadership guide connects mechanistic interpretation, formulation strategy, and translational study design, using the LP.P101 alcohol-associated liver disease study as an evidence anchor.
-
THZ1 Workflow for CDK7 Transcription Studies
2026-09-30
THZ1 provides a covalent, mechanism-focused way to connect CDK7 inhibition with RNA polymerase II control, cell-cycle vulnerability, and apoptosis in cancer models. This workflow shows how to combine short phospho-CTD measurements, washout experiments, viability testing, and checkpoint-aware interpretation for T-cell acute lymphoblastic leukemia research.
-
HLY78: Wnt/β-Catenin Pathway Modulator
2026-09-30
HLY78 is a Wnt/β-catenin pathway modulator that potentiates ligand-dependent signaling through the Axin-LRP6 complex. Research data connect this mechanism with zebrafish embryogenesis and increased cmyb and runx1 expression, but the compound remains a preclinical research tool rather than a clinical therapy.
-
Hexa-Acylated LPS and Cancer Immunotherapy
2026-09-29
This study shows that the functional structure of gut microbiota-derived lipopolysaccharide, rather than bacterial taxonomy alone, can influence response to anti-PD-1 therapy. Hexa-acylated LPS was associated with clinical response and enhanced antitumor immunity in mice through a TLR4-dependent mechanism, while penta-acylated LPS was inactive or antagonistic.
-
HRP Conjugated Anti-Mouse IgG CRC Workflow
2026-09-29
Build sensitive Western blot, ELISA, IHC, and ICC workflows around an affinity-purified HRP secondary antibody. The workflow translates AQP9 and ZHX2 findings in KRASG12V colorectal cancer into practical assay controls, optimization ranges, and troubleshooting decisions.
-
Mapping Pseudouridine on Cellular and HIV-1 RNA
2026-09-28
The study introduces PA-Ψ-seq, an antibody-based, photo-crosslinking method for mapping pseudouridine and applies it to cellular and HIV-1 RNAs. Genetic disruption of PUS1, PUS7, or TRUB1 assigned some cellular mRNA sites to these enzymes, but did not explain most mRNA pseudouridine or the sites detected on HIV-1 transcripts.